3-Dimensional liver volume assessment in patients with hepatitis B virus-related liver cirrhosis during long-term oral nucleos(t)ide analogues therapy

Table 3 Association of liver volume change with independent variables by univariate linear regression analysis

Variables	R2	β	Standard error	P value
Age	0.002	-0.766	2.473	0.758
Body mass index	0.000	-0.419	10.708	0.969
At treatment (baseline)
WBC	0.027	0.016	0.013	0.228
Hemoglobin	0.013	10.858	12.864	0.402
Platelet	0.000	0.050	0.445	0.912
AST	0.162	0.571	0.179	0.002
ALT	0.191	0.483	0.137	0.001
Prothrombin time, INR	0.061	157.794	85.278	0.070
Total bilirubin	0.101	26.334	10.797	0.018
Albumin	0.036	-53.958	38.081	0.162
Creatinine	0.000	-12.157	153.255	0.937
AFP	0.122	0.196	0.072	0.009
Serum HBV DNA	0.014	16.265	18.788	0.391
CTP score	0.070	18.954	9.470	0.050
MELD score	0.081	9.650	4.466	0.035
Follow-up
ALT	0.013	-0.936	1.135	0.414
Prothrombin time, INR	0.097	-415.040	173.546	0.020
Total bilirubin	0.096	-79.343	33.496	0.022
Albumin	0.165	147.769	45.702	0.002
Creatinine	0.015	106.249	116.561	0.366
Serum HBV DNA	0.035	-13.407	9.720	0.174
CTP score	0.068	-39.884	20.313	0.055
MELD score	0.009	-6.209	9.098	0.498
Delta (Follow-up - Baseline)
ALT	0.210	-0.513	0.137	< 0.001
Prothrombin time, INR	0.158	-254.936	80.880	0.003
Total bilirubin	0.158	-31.355	9.943	0.003
Albumin	0.237	132.268	32.604	< 0.001
Creatinine	0.024	151.708	134.270	0.264
Serum HBV DNA improvement (log)	0.084	12.505	5.681	0.032
CTP score	0.236	-49.313	12.183	< 0.001
MELD score	0.126	-12.873	4.655	0.008
Duration of virological response	0.000	-0.016	0.176	0.930

WBC: White blood cell; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; AFP: Alpha fetoprotein; CTP: Child-Turcotte-Pugh; MELD: Model for end-stage liver disease.